BACKGROUND AND OBJECTIVES: AKI occurs frequently in older persons. Elevated circulating fibroblast growth factor-23 (FGF-23), a known marker of impaired mineral metabolism, may also reflect tubular dysfunction and risk of AKI. This study evaluated FGF-23 as well as traditional markers of kidney disease, namely urine albumin-to-creatinine ratio (UACR) and creatinine-cystatin C estimated GFR (eGFRCrCyC), as risk factors for AKI in elderly individuals. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Plasma FGF-23, UACR, and eGFRCrCyC were measured in 3241 community-dwelling elderly individuals in the Cardiovascular Health Study. Hospitalization for AKI was defined by International Classification of Diseases, Ninth Revision, Clinical Modification codes. Associations of each biomarker with AKI were evaluated using Cox proportional hazards models adjusted for demographics, cardiovascular risk factors, and biomarkers of kidney function. RESULTS: The mean participant age was 78 years; 60% of participants were women and 16% were African American. The median (interquartile range) values of biomarkers were as follows: FGF-23, 70 RU/ml (53, 99); UACR, 8.88 mg/g (4.71, 20.47); and eGFRCrCyC, 71 ml/min per 1.73 m(2) (59, 83). Hospitalized AKI occurred in 119 participants over 10.0 years of median follow-up. In fully adjusted analyses, compared with the lowest quartiles, the highest quartiles of FGF-23 (≥100 RU/ml) and UACR (≥20.9 mg/g) were associated with AKI (FGF-23: hazard ratio [HR], 1.99; 95% confidence interval [95% CI], 1.04 to 3.80; and UACR: HR, 3.35; 95% CI, 1.83 to 6.13). Compared with the highest quartile, the lowest quartile of eGFRCrCyC (<57 ml/min per 1.73 m(2)) was associated with AKI with an HR of 2.15 (95% CI, 1.21 to 3.82). CONCLUSIONS: FGF-23 adjusted for albuminuria, cardiovascular disease risk factors, and baseline eGFR is independently associated with a higher risk of AKI hospitalizations in community-dwelling elderly individuals. Further studies to understand the nature of this association are warranted.
BACKGROUND AND OBJECTIVES: AKI occurs frequently in older persons. Elevated circulating fibroblast growth factor-23 (FGF-23), a known marker of impaired mineral metabolism, may also reflect tubular dysfunction and risk of AKI. This study evaluated FGF-23 as well as traditional markers of kidney disease, namely urine albumin-to-creatinine ratio (UACR) and creatinine-cystatin C estimated GFR (eGFRCrCyC), as risk factors for AKI in elderly individuals. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Plasma FGF-23, UACR, and eGFRCrCyC were measured in 3241 community-dwelling elderly individuals in the Cardiovascular Health Study. Hospitalization for AKI was defined by International Classification of Diseases, Ninth Revision, Clinical Modification codes. Associations of each biomarker with AKI were evaluated using Cox proportional hazards models adjusted for demographics, cardiovascular risk factors, and biomarkers of kidney function. RESULTS: The mean participant age was 78 years; 60% of participants were women and 16% were African American. The median (interquartile range) values of biomarkers were as follows: FGF-23, 70 RU/ml (53, 99); UACR, 8.88 mg/g (4.71, 20.47); and eGFRCrCyC, 71 ml/min per 1.73 m(2) (59, 83). Hospitalized AKI occurred in 119 participants over 10.0 years of median follow-up. In fully adjusted analyses, compared with the lowest quartiles, the highest quartiles of FGF-23 (≥100 RU/ml) and UACR (≥20.9 mg/g) were associated with AKI (FGF-23: hazard ratio [HR], 1.99; 95% confidence interval [95% CI], 1.04 to 3.80; and UACR: HR, 3.35; 95% CI, 1.83 to 6.13). Compared with the highest quartile, the lowest quartile of eGFRCrCyC (<57 ml/min per 1.73 m(2)) was associated with AKI with an HR of 2.15 (95% CI, 1.21 to 3.82). CONCLUSIONS:FGF-23 adjusted for albuminuria, cardiovascular disease risk factors, and baseline eGFR is independently associated with a higher risk of AKI hospitalizations in community-dwelling elderly individuals. Further studies to understand the nature of this association are warranted.
Authors: Michael G Shlipak; Ronit Katz; Mary Cushman; Mark J Sarnak; Catherine Stehman-Breen; Bruce M Psaty; David Siscovick; Russell P Tracy; Anne Newman; Linda Fried Journal: Am J Med Date: 2005-12 Impact factor: 4.965
Authors: Matthew T James; Brenda R Hemmelgarn; Natasha Wiebe; Neesh Pannu; Braden J Manns; Scott W Klarenbach; Marcello Tonelli Journal: Lancet Date: 2010-11-20 Impact factor: 79.321
Authors: Elsbeth C Witte; Hiddo J Lambers Heerspink; Dick de Zeeuw; Stephan J L Bakker; Paul E de Jong; Ronald Gansevoort Journal: J Am Soc Nephrol Date: 2008-12-17 Impact factor: 10.121
Authors: Vishal S Vaidya; Sushrut S Waikar; Michael A Ferguson; Fitz B Collings; Kelsey Sunderland; Costas Gioules; Gary Bradwin; Roland Matsouaka; Rebecca A Betensky; Gary C Curhan; Joseph V Bonventre Journal: Clin Transl Sci Date: 2008-12 Impact factor: 4.689
Authors: Morgan E Grams; Brad C Astor; Lori D Bash; Kunihiro Matsushita; Yaping Wang; Josef Coresh Journal: J Am Soc Nephrol Date: 2010-07-29 Impact factor: 10.121
Authors: Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: Dena E Rifkin; Ronit Katz; Michel Chonchol; Linda F Fried; Jie Cao; Ian H de Boer; David S Siscovick; Michael G Shlipak; Mark J Sarnak Journal: Nephrol Dial Transplant Date: 2009-12-15 Impact factor: 5.992
Authors: Anuja Mittalhenkle; Catherine O Stehman-Breen; Michael G Shlipak; Linda F Fried; Ronit Katz; Bessie A Young; Stephen Seliger; Daniel Gillen; Anne B Newman; Bruce M Psaty; David Siscovick Journal: Clin J Am Soc Nephrol Date: 2008-02-06 Impact factor: 8.237
Authors: Carmen A Peralta; Ronit Katz; Mark J Sarnak; Joachim Ix; Linda F Fried; Ian De Boer; Walter Palmas; David Siscovick; Andrew S Levey; Michael G Shlipak Journal: J Am Soc Nephrol Date: 2010-12-16 Impact factor: 14.978
Authors: Amarnath Marthi; Killian Donovan; Richard Haynes; David C Wheeler; Colin Baigent; Christopher M Rooney; Martin J Landray; Sharon M Moe; Jun Yang; Lisa Holland; Romina di Giuseppe; Annet Bouma-de Krijger; Borislava Mihaylova; William G Herrington Journal: J Am Soc Nephrol Date: 2018-05-15 Impact factor: 10.121
Authors: Alvaro Alonso; Jeffrey R Misialek; John H Eckfeldt; Elizabeth Selvin; Josef Coresh; Lin Y Chen; Elsayed Z Soliman; Sunil K Agarwal; Pamela L Lutsey Journal: J Am Heart Assoc Date: 2014-09-18 Impact factor: 5.501